These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 24821107)
1. DNA methylation profiles in ovarian cancer: implication in diagnosis and therapy (Review). Koukoura O; Spandidos DA; Daponte A; Sifakis S Mol Med Rep; 2014 Jul; 10(1):3-9. PubMed ID: 24821107 [TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature. Aref-Eshghi E; McGee JD; Pedro VP; Kerkhof J; Stuart A; Ainsworth PJ; Lin H; Volodarsky M; McLachlin CM; Sadikovic B J Hum Genet; 2020 Oct; 65(10):865-873. PubMed ID: 32483276 [TBL] [Abstract][Full Text] [Related]
3. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls. Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934 [TBL] [Abstract][Full Text] [Related]
4. Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia. Pradjatmo H Asian Pac J Cancer Prev; 2015; 16(18):8599-604. PubMed ID: 26745123 [TBL] [Abstract][Full Text] [Related]
5. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Barton CA; Hacker NF; Clark SJ; O'Brien PM Gynecol Oncol; 2008 Apr; 109(1):129-39. PubMed ID: 18234305 [TBL] [Abstract][Full Text] [Related]
6. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma. S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147 [TBL] [Abstract][Full Text] [Related]
7. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Swisher EM; Gonzalez RM; Taniguchi T; Garcia RL; Walsh T; Goff BA; Welcsh P Mol Cancer; 2009 Jul; 8():48. PubMed ID: 19602291 [TBL] [Abstract][Full Text] [Related]
9. Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation. Pradhan M; Risberg BA; Tropé CG; van de Rijn M; Gilks CB; Lee CH BMC Cancer; 2010 Sep; 10():493. PubMed ID: 20843305 [TBL] [Abstract][Full Text] [Related]
10. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation. Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression. Wang YQ; Yan Q; Zhang JR; Li SD; Yang YX; Wan XP J Obstet Gynaecol Res; 2013 Feb; 39(2):549-54. PubMed ID: 23006047 [TBL] [Abstract][Full Text] [Related]
12. Genome-wide DNA methylation as an epigenetic consequence of Epstein-Barr virus infection of immortalized keratinocytes. Birdwell CE; Queen KJ; Kilgore PC; Rollyson P; Trutschl M; Cvek U; Scott RS J Virol; 2014 Oct; 88(19):11442-58. PubMed ID: 25056883 [TBL] [Abstract][Full Text] [Related]
13. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells. Cardenas H; Vieth E; Lee J; Segar M; Liu Y; Nephew KP; Matei D Epigenetics; 2014 Nov; 9(11):1461-72. PubMed ID: 25470663 [TBL] [Abstract][Full Text] [Related]
14. Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses. Wang Z; Zhang J; Zhang Y; Deng Q; Liang H Int J Mol Med; 2018 Dec; 42(6):3542-3550. PubMed ID: 30221688 [TBL] [Abstract][Full Text] [Related]
15. DNA methylation and demethylation as targets for anticancer therapy. Szyf M Biochemistry (Mosc); 2005 May; 70(5):533-49. PubMed ID: 15948707 [TBL] [Abstract][Full Text] [Related]
16. Recently identified drug resistance biomarkers in ovarian cancer. Davidson B Expert Rev Mol Diagn; 2016; 16(5):569-78. PubMed ID: 26895188 [TBL] [Abstract][Full Text] [Related]
17. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. Wrzeszczynski KO; Varadan V; Byrnes J; Lum E; Kamalakaran S; Levine DA; Dimitrova N; Zhang MQ; Lucito R PLoS One; 2011; 6(12):e28503. PubMed ID: 22174824 [TBL] [Abstract][Full Text] [Related]
18. Epigenetic modulation of BRCA1 and BRCA2 gene expression by equol in breast cancer cell lines. Bosviel R; Durif J; Déchelotte P; Bignon YJ; Bernard-Gallon D Br J Nutr; 2012 Oct; 108(7):1187-93. PubMed ID: 22217331 [TBL] [Abstract][Full Text] [Related]
19. The DNA methylome of cervical cells can predict the presence of ovarian cancer. Barrett JE; Jones A; Evans I; Reisel D; Herzog C; Chindera K; Kristiansen M; Leavy OC; Manchanda R; Bjørge L; Zikan M; Cibula D; Widschwendter M Nat Commun; 2022 Feb; 13(1):448. PubMed ID: 35105887 [TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid receptor repression mediated by BRCA1 inactivation in ovarian cancer. Fang YY; Li D; Cao C; Li CY; Li TT BMC Cancer; 2014 Mar; 14():188. PubMed ID: 24629067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]